Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 458

1.

Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.

Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A.

Breast Cancer Res Treat. 2018 May 22. doi: 10.1007/s10549-018-4828-5. [Epub ahead of print]

PMID:
29789969
2.

Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.

Morris PG, Rota S, Cadoo K, Zamora S, Patil S, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Norton L, Hudis CA, Fornier MN.

Clin Breast Cancer. 2018 Mar 15. pii: S1526-8209(17)30810-8. doi: 10.1016/j.clbc.2018.03.010. [Epub ahead of print]

PMID:
29680193
3.

The Impact of Obesity on Breast Cancer.

Argolo DF, Hudis CA, Iyengar NM.

Curr Oncol Rep. 2018 Apr 11;20(6):47. doi: 10.1007/s11912-018-0688-8. Review.

PMID:
29644507
4.

A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.

Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ.

Cancer Prev Res (Phila). 2018 Apr;11(4):203-214. doi: 10.1158/1940-6207.CAPR-17-0354. Epub 2018 Feb 16.

PMID:
29453232
5.

Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

Morikawa A, Wang R, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD.

Clin Breast Cancer. 2017 Dec 21. pii: S1526-8209(17)30394-4. doi: 10.1016/j.clbc.2017.12.009. [Epub ahead of print]

PMID:
29337140
6.

Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.

Turashvili G, Brogi E, Morrow M, Dickler M, Norton L, Hudis C, Wen HY.

BMC Cancer. 2018 Jan 6;18(1):42. doi: 10.1186/s12885-017-3985-y.

7.

Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women.

Alemán JO, Iyengar NM, Walker JM, Milne GL, Da Rosa JC, Liang Y, Giri DD, Zhou XK, Pollak MN, Hudis CA, Breslow JL, Holt PR, Dannenberg AJ.

J Endocr Soc. 2017 Apr 25;1(6):625-637. doi: 10.1210/js.2017-00020. eCollection 2017 Jun 1.

8.

Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women.

Iyengar NM, Chen IC, Zhou XK, Giri DD, Falcone DJ, Winston LA, Wang H, Williams S, Lu YS, Hsueh TH, Cheng AL, Hudis CA, Lin CH, Dannenberg AJ.

Cancer Prev Res (Phila). 2018 Apr;11(4):227-236. doi: 10.1158/1940-6207.CAPR-17-0283. Epub 2017 Dec 8.

PMID:
29222346
9.

Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas.

Kunitake JAMR, Choi S, Nguyen KX, Lee MM, He F, Sudilovsky D, Morris PG, Jochelson MS, Hudis CA, Muller DA, Fratzl P, Fischbach C, Masic A, Estroff LA.

J Struct Biol. 2018 Apr;202(1):25-34. doi: 10.1016/j.jsb.2017.12.002. Epub 2017 Dec 6.

PMID:
29221896
10.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

PMID:
29208398
11.

Leptin regulation of the p53-HIF1α/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link.

Zahid H, Subbaramaiah K, Iyengar NM, Zhou XK, Chen IC, Bhardwaj P, Gucalp A, Morrow M, Hudis CA, Dannenberg AJ, Brown KA.

Int J Obes (Lond). 2018 Apr;42(4):711-720. doi: 10.1038/ijo.2017.273. Epub 2017 Nov 6.

12.

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH.

Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651.

PMID:
29092024
13.

American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action.

Ligibel JA, Alfano CM, Hershman DL, Merrill JK, Basen-Engquist K, Bloomgarden ZT, Demark-Wahnefried W, Dixon S, Hassink SG, Jakicic JM, Morton JM, Okwuosa TM, Powell-Wiley TM, Rothberg AE, Stephens M, Streett SE, Wild RA, Westman EA, Williams RJ, Wollins DS, Hudis CA.

Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S34-S39. doi: 10.1002/oby.21987.

PMID:
29086516
14.

Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.

Page DB, Wen H, Brogi E, Dure D, Ross D, Spinelli KJ, Patil S, Norton L, Hudis C, McArthur HL.

Breast Cancer Res Treat. 2018 Jan;167(2):547-554. doi: 10.1007/s10549-017-4520-1. Epub 2017 Oct 6.

PMID:
28986743
15.

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design.

Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ.

NPJ Breast Cancer. 2017 Sep 21;3:37. doi: 10.1038/s41523-017-0040-8. eCollection 2017. Review.

16.

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.

PMID:
28830796
17.

Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302).

Hopkins JO, Allred J, Hurria A, Jatoi A, Lafky JM, Cohen H, Hudis C, Winer E, Mandelblatt J, Partridge A, Carey L, Muss HB.

Breast Cancer Res Treat. 2017 Dec;166(3):793-808. doi: 10.1007/s10549-017-4454-7. Epub 2017 Aug 20.

PMID:
28825227
18.

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.

Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, O'Neill T, Friedman K, Esteva FJ, Hudis C, Modi S.

Breast Cancer Res. 2017 Aug 2;19(1):89. doi: 10.1186/s13058-017-0879-5.

19.

Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.

Yu AF, Mukku RB, Verma S, Liu JE, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.

Breast Cancer Res Treat. 2017 Nov;166(1):241-247. doi: 10.1007/s10549-017-4362-x. Epub 2017 Jul 14.

PMID:
28710537
20.

21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.

Turashvili G, Chou JF, Brogi E, Morrow M, Dickler M, Norton L, Hudis C, Wen HY.

Breast Cancer Res Treat. 2017 Nov;166(1):69-76. doi: 10.1007/s10549-017-4381-7. Epub 2017 Jul 12.

21.

Periprostatic adipose inflammation is associated with high-grade prostate cancer.

Gucalp A, Iyengar NM, Zhou XK, Giri DD, Falcone DJ, Wang H, Williams S, Krasne MD, Yaghnam I, Kunzel B, Morris PG, Jones LW, Pollak M, Laudone VP, Hudis CA, Scher HI, Scardino PT, Eastham JA, Dannenberg AJ.

Prostate Cancer Prostatic Dis. 2017 Dec;20(4):418-423. doi: 10.1038/pcan.2017.31. Epub 2017 Jun 27.

22.

Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score.

Mariotti V, Page DB, Davydov O, Hans D, Hudis CA, Patil S, Kunte S, Girotra M, Farooki A, Fornier MN.

J Bone Oncol. 2016 Oct 18;7:32-37. doi: 10.1016/j.jbo.2016.10.004. eCollection 2017 Jun.

23.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV.

AAPS J. 2017 Sep;19(5):1411-1423. doi: 10.1208/s12248-017-0101-9. Epub 2017 Jun 15.

PMID:
28620884
24.

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.

Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D.

JAMA. 2017 Jul 11;318(2):197-198. doi: 10.1001/jama.2017.7156. No abstract available.

25.

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.

Turashvili G, Brogi E, Morrow M, Hudis C, Dickler M, Norton L, Wen HY.

Breast Cancer Res Treat. 2017 Aug;165(1):65-76. doi: 10.1007/s10549-017-4326-1. Epub 2017 Jun 3.

PMID:
28577081
26.

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J.

Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22.

PMID:
28533223
27.

Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).

Mandelblatt JS, Cai L, Luta G, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A.

Breast Cancer Res Treat. 2017 Jul;164(1):107-117. doi: 10.1007/s10549-017-4222-8. Epub 2017 Mar 31.

28.

Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement.

Visvanathan K, Levit LA, Raghavan D, Hudis CA, Wong S, Dueck A, Lyman GH.

J Clin Oncol. 2017 Jun 1;35(16):1845-1854. doi: 10.1200/JCO.2017.72.6414. Epub 2017 Mar 30.

PMID:
28358653
29.

Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.

Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.

Oncologist. 2017 Jun;22(6):642-647. doi: 10.1634/theoncologist.2016-0406. Epub 2017 Mar 24.

30.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Dec 1;28(12):3111. doi: 10.1093/annonc/mdx036. No abstract available.

31.

Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers.

Brown KA, Iyengar NM, Zhou XK, Gucalp A, Subbaramaiah K, Wang H, Giri DD, Morrow M, Falcone DJ, Wendel NK, Winston LA, Pollak M, Dierickx A, Hudis CA, Dannenberg AJ.

J Clin Endocrinol Metab. 2017 May 1;102(5):1692-1701. doi: 10.1210/jc.2016-3606.

32.

Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).

Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, Barginear M, Freedman RA, Artz A, Klepin HD, Lafky JM, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A, Mandelblatt J.

Breast Cancer Res Treat. 2017 Jun;163(2):391-398. doi: 10.1007/s10549-017-4188-6. Epub 2017 Mar 10.

33.

Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.

Iyengar NM, Brown KA, Zhou XK, Gucalp A, Subbaramaiah K, Giri DD, Zahid H, Bhardwaj P, Wendel NK, Falcone DJ, Wang H, Williams S, Pollak M, Morrow M, Hudis CA, Dannenberg AJ.

Cancer Prev Res (Phila). 2017 Apr;10(4):235-243. doi: 10.1158/1940-6207.CAPR-16-0314. Epub 2017 Mar 7.

34.

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R, Generali D.

Eur J Cancer. 2017 Apr;75:245-258. doi: 10.1016/j.ejca.2017.01.026. Epub 2017 Feb 24. Review.

PMID:
28242502
35.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. No abstract available. Erratum in: Ann Oncol. 2017 Dec 1;28(12 ):3111.

36.

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.

Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, Yu AF, Argolo D, Smyth LM, Modi S, Schweber S, Boafo C, Patil S, Norton L, Baselga J, Hudis CA, Dang C.

Oncologist. 2017 Feb;22(2):139-143. doi: 10.1634/theoncologist.2016-0268. Epub 2017 Feb 6.

37.

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Breast. 2017 Apr;32:269-270. doi: 10.1016/j.breast.2017.01.001. Epub 2017 Jan 18. No abstract available.

PMID:
28109648
38.

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M.

J Am Coll Surg. 2017 Apr;224(4):688-694. doi: 10.1016/j.jamcollsurg.2016.12.036. Epub 2017 Jan 13.

39.

Reply to L.B. Marks et al.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

J Clin Oncol. 2017 Apr 10;35(11):1258-1259. doi: 10.1200/JCO.2016.71.3966. Epub 2017 Jan 9. No abstract available.

PMID:
28068171
40.

Docosahexaenoic Acid Supplementation is Not Anti-Inflammatory in Adipose Tissue of Healthy Obese Postmenopausal Women.

Holt PR, Alemán JO, Walker JM, Jiang CS, Liang Y, de Rosa JC, Giri DD, Iyengar NM, Milne GL, Hudis CA, Breslow JL.

Int J Nutr. 2017;1(4):31-49. doi: 10.14302/issn.2379-7835.ijn-17-1636. Epub 2017 Jul 21.

41.

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A.

J Clin Oncol. 2017 Feb;35(4):421-431. doi: 10.1200/JCO.2016.69.4182. Epub 2016 Dec 19.

42.

Estimating the OncotypeDX score: validation of an inexpensive estimation tool.

Eaton AA, Pesce CE, Murphy JO, Stempel MM, Patil SM, Brogi E, Hudis CA, El-Tamer M.

Breast Cancer Res Treat. 2017 Feb;161(3):435-441. doi: 10.1007/s10549-016-4069-4. Epub 2016 Dec 7.

43.

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Breast. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5. No abstract available.

44.

Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation.

Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA.

J Clin Oncol. 2016 Dec 10;34(35):4270-4276. Epub 2016 Nov 7. Review.

45.

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB.

Breast Cancer Res Treat. 2017 Jan;161(2):363-373. doi: 10.1007/s10549-016-4051-1. Epub 2016 Nov 19.

46.

Research needs in breast cancer.

Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA.

Ann Oncol. 2017 Feb 1;28(2):208-217. doi: 10.1093/annonc/mdw571.

PMID:
27831505
47.

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.

Clin Cancer Res. 2016 Dec 1;22(23):5729-5737. Epub 2016 Aug 26.

48.

The epichaperome is an integrated chaperome network that facilitates tumour survival.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G.

Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807. Epub 2016 Oct 5.

49.

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Breast Cancer Res Treat. 2016 Nov;160(2):297-304. Epub 2016 Oct 4.

50.

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):e219-e234. doi: 10.1016/j.prro.2016.08.009. Epub 2016 Sep 19. Review.

PMID:
27659727

Supplemental Content

Support Center